ArticleOrphanet journal of rare diseases2025
Population-based estimates of the global prevalence and carrier frequency of apparent mineralocorticoid excess caused by 11β-hydroxysteroid dehydrogenase type 2 deficiency.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApparent mineralocorticoid excess (AME) is a rare autosomal recessive disorder caused by biallelic inactivating variants in the HSD11B2 gene resulting in hypertension and electrolyte abnormalities due to cortisol-mediated activation of mineralocorticoid receptors. We aimed to utilize data from a large genomic database to estimate the prevalence and carrier frequency of AME, with stratification by ethnic ancestry to identify potential disparities.
methodsWe analyzed sequencing data from 807,162 unrelated individuals in the gnomAD v4.1 database, representing diverse ethnic ancestries. Potentially disease-causing HSD11B2 variants were identified using three approaches: classification as pathogenic/likely pathogenic (P/LP) in ClinVar, association with AME based on systematic review of the literature, or predicted deleterious effects by in silico tools. Carrier frequency was calculated based on combined allele frequencies. Disease prevalence was estimated using Hardy-Weinberg equilibrium assumptions. Analyses were stratified by ancestry and variant selection criteria.
resultsOf 1,506 HSD11B2 variants in gnomAD, 160 qualified as potentially pathogenic. Using strict criteria (ClinVar/literature), the global carrier frequency was 24.5/100,000 individuals and disease prevalence was 0.6/10,000,000. With liberal criteria (including in silico predictions), these increased to 82.6/100,000 and 6.8/10,000,000. The highest carrier frequencies were observed in Middle Eastern individuals (132.0/100,000 under strict criteria) and South Asians (147.1/100,000 under liberal criteria). Several variants were enriched in specific populations.
conclusionThis study provides the first global, ancestry-stratified estimates of AME carrier frequency and prevalence, revealing variability by ancestry and variant classification. Results highlight the need for improved variant curation and broader population representation in genomic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.